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b-Defensins-3 Activate LCs and Exacerbate PsoriasisOur data show that one-third of
patients with PD have autoantibodies
to Col XVII that also bind to THþ neu-
rons. The lack of reactivity of PD auto-
antibodies with skin suggests the
autoantibodies develop from neuronal
Col XVII. The subset of patients with
neurologic disease that develop BP
likely result from epitope spreading to
regions of Col XVII that are pathogenic
in skin. A key question that remains is
whether Col XVII autoantibodies have a
detrimental effect on PD or are other-
wise predictive of disease onset/out-
comes. Finally, these data suggest loss
of tolerance to neuronal Col XVII may
contribute to the risk for pemphigoid.
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Genetic variations in the proin-
flammatory cytokine IL-23 are associ-
ated with psoriasis, a common,
inflammatory skin disorder (Nair et al.,
2009). IL-23 is primarily produced by
dendritic cells (DCs) and plays a path-
ogenic role in psoriasis by directing thedevelopment of T helper type 17 cells
(Di Cesare et al., 2009). Langerhans
cells (LCs), the main DC subtype in the
epidermis, can participate in both im-
munity and the induction of tolerance
(Igyarto et al., 2011; Seneschal et al.,
2012), yet their role in psoriasis re-
mains unclear. Mouse models ofdisease have yielded contradictory re-
sults (Glitzner et al., 2014; Wohn et al.,
2013; Yoshiki et al., 2014). However,
the migration of LCs is impaired in
human disease, and it was suggested
that the inflammatory environment
of psoriasis may affect their function
(Cumberbatch et al., 2006). This study
sought to clarify the role of LC role in
disease with specific focus on the pro-
duction of IL-23.
Punch biopsies (6 mm) were obtained
from psoriasis patients and healthywww.jidonline.org 723
Figure 1. IL-23 production by Langerhans cells (LCs) is enhanced in psoriasis. (a) Epidermal suspensions from healthy controls and psoriasis patients were
treated with monensin for 6 hours and IL-23 expression by LCs (live, CD45þCD1aþCD207 cells) was analyzed by flow cytometry. Results are given as
mean  standard error of the mean for 6e8 donors. (b) Monocyte-derived LCs from psoriasis patients (PSOR) and controls (HC) were stimulated with zymosan
(10 mg/ml). After 24 hours, the concentration of IL-23 was determined by ELISA. (c, d) Epidermal LCs from psoriasis patients (PSOR) and healthy controls (HC)
were treated with (c) zymosan or (d) human b-defensin 3 (HBD3) for 24 hours. Monensin was added for the final 12 hours, and the expression of IL-23 by
LCs was determined by flow cytometry. Results are given as mean  standard error of the mean for 4e8 donors. Representative plots are pregated on live
CD45þCD207þCD1aþ LCs. (e) IL-23 expression by epidermal LCs from psoriasis patients (PSOR) and healthy controls (HC) (as in d). Results are given as
mean  standard error of the mean for 6e8 donors, *P < 0.05, **P < 0.01, ***P < 0.001.
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724controls after written informed patient
consent and ethical approval were ob-
tained from St. Vincent’s Ethics and
Medical Research Committee. LCs in
epidermal suspensions were identified
as live single CD45þCD1aþCD207þ
cells (Figure 1a; see Supplementary
Materials online). A significantly higher
percentage of epidermal LCs expressed
IL-23p19 or coexpressed p40 and p19
in psoriatic lesional and perilesional
biopsies compared with LCs from
healthy epidermis (P < 0.01, P < 0.05;
Figure 1a). There was no significantJournal of Investigative Dermatology (2016), Volumdifference in the expression of IL-12p40
only (Figure 1a). These results suggest
that under inflammatory conditions, LCs
are capable of producing proin-
flammatory cytokines that promote T
helper type 17 cell development.
Since monocyte-derived LCs (moLCs)
play an important role in repopulating
the epidermis during inflammation-
induced migration (Ginhoux et al.,
2006), we next examined IL-23 pro-
duction by moLCs. LC differentiation
was confirmed by examining the
expression of CD1a, E-cadherin, ande 136CD207 (see Supplementary Figure S1
online). moLCs from psoriasis patients
were found to express significantly
higher levels of IL-23 upon zymosan
stimulation compared with moLCs from
healthy controls (P < 0.01; Figure 1b).
Furthermore, although zymosan in-
duced a small but significant expression
of IL-23 by epidermal LCs from healthy
controls (P< 0.05; Figure 1c), it induced
significantly more IL-23 by epidermal
LCs from psoriasis patients, suggesting
that factors associated with the inflam-
matory microenvironment of psoriasis
Figure 2. Human b-defensin 3 (HBD3) is enhanced in psoriasis and its ortholog mouse b-defensin 14 (MBD14) exacerbates psoriasis-like inflammation
in mice, which is associated with an increase in IL-23p19 expression by Langerhans cells (LCs). (a) HBD3 mRNA and (b) protein expression was determined
in the (a) skin (n ¼ 8) and (b) serum (n ¼ 25) of psoriasis patients before and after (n ¼ 6e7) treatment and from control skin (HC; n ¼ 3) and serum (HC; n ¼ 13)
by reverse transcriptase-PCR and ELISA, respectively. (c) Psoriasis-like skin disease was induced in C57BL/6 mice with topical application of Aldara cream;
intradermal administration of MBD14 (1 mg in phosphate buffered saline) and topical application of Aldara; or intradermal administration of MBD14 (1 mg
in phosphate buffered saline) only for 7 days. Matched control ears received vehicle treatment. (c) Ear thickness was measured using a thickness gauge (Hitec)
before initiation of the experiment on day 0 and every day for 7 days. Clinical thickness of control (vehicle) and treated ears are shown as mean score  standard
error of the mean (n ¼ 5e6). (d, e) Ears from mice were removed and frozen in optimal cutting temperature compound. (d) Psoriasis severity and (e) expression
of IL-23p19 (red) by LCs (green) counterstained with 40,6-diamidino-2-phenylindole (DAPI; blue) were determined using hematoxylin and eosin staining and
three-color immunofluorescence, respectively. Bar ¼ 100 mm. (d) Representative control image displayed. (e) High magnification inset (magnification 60) from
displayed images are depicted. Magnification 40 also depicted for MBD14&Aldara group (bottom inset). (f) Percentage of IL-23þ LCs shown as mean score 
standard error of the mean. n ¼ 5e6, *P < 0.05, **P < 0.01, ***P < 0.001.
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726cooperate with zymosan to promote IL-
23 expression. We next sought to deter-
mine the mechanism driving IL-23
expression by LCs in psoriasis. Antimi-
crobial peptides in complex with self-
nucleotides have been implicated in
the pathogenesis of psoriasis through
the production of proinflammatory cy-
tokines by plasmacytoid (Lande et al.,
2007) and myeloid DC (Ganguly et al.,
2009). Human b-defensin 3 (HBD3), a
small antimicrobial peptide, is chemo-
tactic for immune cells and is enhanced
in psoriasis (Lande et al., 2015). HBD3
in complexwith self-DNA (Tewary et al.,
2013) was shown to induce IFN-a pro-
duction by plasmacytoid DC (Tewary
et al., 2013) and in cooperation with
other antimicrobial peptides can break
tolerance to self-DNA (Lande et al.,
2015). Other studies have shown that
HBD3 alone enhances the expression of
costimulatory molecules on LCs (Ferris
et al., 2013), suggesting that HBD3
may modulate antigen-presenting cells
in psoriasis. Given its effects on LCs, we
examined whether HBD3 plays a role in
the dysregulation of LCs in psoriasis.
HBD3 induced IL-23 and enhanced
zymosan-induced IL-23 production by
healthy moLCs (see Supplementary
Figure S2 online). Moreover, HBD3
alone induced the production of IL-23
by epidermal LCs from psoriasis pa-
tients and healthy controls (P < 0.01;
Figure 1d). However, HBD3-induced
IL-23 production was significantly
increased in psoriasis patients compared
with healthy controls (P < 0.01;
Figure 1e), suggesting that increased IL-
23 in psoriasis is a result of HBD3 and
the psoriatic environment (possibly
endogenous HBD3). These results indi-
cate that HBD3 may play a pathogenic
role in psoriasis.
We next examined the expression of
HBD3 in psoriasis. The mRNA expres-
sion of HBD3 was increased in psoria-
sis skin during active disease and
decreased upon clearance of psoriasis
with UVB treatment to levels compa-
rable with that of healthy controls
(P < 0.05; Figure 2a). Similar results
were obtained in the serum (P < 0.01;
P < 0.05, Figure 2b). To confirm the
pathogenic role of HBD3 in psoriasis,
we next examined the effect of HBD3
in a murine model of disease. Psoriasis-
like skin inflammation was induced
in C57BL/6 mice with imiquimodJournal of Investigative Dermatology (2016), Volumformulated in a commercially available
cream (Aldara, MEDA Pharmaceuticals,
Dublin, Ireland); Aldara and murine b-
defensin 14 (MBD14), a murine ortho-
log of HBD3 (Hinrichsen et al., 2008);
or MBD14 only for 7 days. As expected,
application of Aldara cream resulted
in psoriasis-like skin inflammation
as measured by increased epidermal
thickness (Figure 2c), acanthosis,
desquamation, parakeratosis, and infil-
tration (Figure 2d). However, MBD14
exacerbated epidermal ear thickness
and psoriasis-like skin inflammation
(P < 0.01, P < 0.001; Figure 2c and d),
and MBD14 alone induced a mild dis-
ease (Figure 2c and d). To investigate
the role of LCs in this model,
we examined IL-23p19 expression by
LCs by immunofluorescence (see
Supplementary Materials). IL-23p19
was strongly expressed in ears that
received Aldara or Aldara plus MBD14
(Figure 2e) but was absent in control
skin (Figure 2e). From 25% to 35% of
LCs expressed IL-23p19 in epidermis
from inflamed skin (Figure 2f) induced
with Aldara (mean 25.64%) or Aldara
plus MBD14 (mean 35.4%). In accor-
dance with a milder clinical pheno-
type, 15% of LCs expressed IL-23p19 in
epidermis from mice treated with
MBD14 only (Figure 2f). These results
suggest that MBD14 exacerbates
psoriasis-like skin inflammation and
alone induces a mild disease in mice,
which is associated with an increased
expression of IL-23p19 by LCs. This
strongly suggests that HBD3 plays a
pathogenic role in psoriasis by pro-
moting the expression of IL-23 by LCs
and that LCs likely act as sources of IL-
23 in disease. Recent studies
have demonstrated that conventional
langerin-negative DC produce IL-23 to
induce psoriasis-like inflammation in
mice and suggest that LCs are dispens-
able for the induction of disease (Wohn
et al., 2013). In contrast, it was shown
that LCs are a major DC source of IL-23
during psoriasis-like inflammation and
are essential for disease induction
(Yoshiki et al., 2014). It is worth noting
that each of these studies differed in
their precise methods of disease in-
duction or LC ablation but established
IL-23 as a key player in driving
psoriasis-like inflammation. Although it
is unclear whether LCs play a role in the
induction of psoriasis-like inflammatione 136in mice, our results demonstrate that
LCs are capable of producing IL-23 in
disease. Thus, it may be that although
LCs are not necessary for the initial in-
duction of disease, activation of LCs by
HBD3 sustains and amplifies an estab-
lished inflammatory response. Regard-
less, our study clearly demonstrates that
HBD3 drives the production of IL-23 by
LCs in psoriasis, which contributes to
the pathogenesis of disease.
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The solar radiation spectrum reaching
the earth’s surface consists mostly
of ultraviolet A (UVA), visible, and
infrared light. UVA irradiation has clin-
ical applications for patients requiring
local immune-suppression therapy
(Weatherhead et al., 2012). However,
UV radiation is carcinogenic and is not
recommended for long-term treatment
(Kunisada et al., 2007). Thus, visible
light-based therapies with less harmful
effects on human skin are desirable. For
example, blue light (400e450 nm) irra-
diation is used therapeutically to treat
severe atopic dermatitis (Becker et al.,
2011), 632.8-nm light enhances cell
proliferation, and red light (550e670
nm) accelerates epidermal permeability
barrier recovery after disruption (Denda
and Fuziwara, 2008; Hu et al., 2007).
However, the mechanisms underlying
various effects of visible light are not
clear.Human skin exhibits innate immune
responses, such as epithelial defense
via antimicrobial peptides (AMPs), and
the release of proinflammatory cyto-
kines involved in the recognition of
microbes via toll-like receptors (TLRs)
(Gallo and Nakatsuji, 2011; Meyer
et al., 2007). Thus, we investigated the
effects of visible light on innate immu-
nity. The survival rate of normal human
epithelial keratinocytes (NHEKs) was
not affected by visible light irradiation
(Supplementary Figure S1 online). Vio-
let or blue light downregulated the
mRNA expression levels of AMPs after
one or three exposures (Figure 1a, b
and Supplementary Figure S2a online).
By contrast, UV irradiation upregulated
AMPs, except for LL-37 (Supplementary
Figure S2b). The expression levels
of AMPs (human beta-defensins (HBD-
1, -3)) and proinflammatory cytokines
(RANTES, MCP-1, and IL-8) decreased
after violet light irradiation in 3D skin(Supplementary Figure S2c). This violet
light-induced downregulation of AMPs
affected bacterial survival. Bacteria
grew better in a violet light-irradiated
NHEK-conditioned medium than
in a control NHEK-conditioned me-
dium, irrespective of polyinosinic-
polycytidylic acid (poly I:C), which
amplifies innate immune responses
(Supplementary Figure S3 online).
We examined whether violet light in-
fluences TLR ligand-induced responses.
Poly I:C, but not Pam3, lipopolysaccha-
ride, or CpG, increased HBD-1, -2, and
-3 simultaneously, which was signifi-
cantly decreased by violet light.
Flagellin-induced increases in HBD-2
and S100A7were reduced by violet light
(Figure 1c). Poly I:C-induced increases
in proinflammatory cytokines were
decreased by violet light in NHEKs and
3D models (Supplementary Figure S4a
online). Unlike violet light, red light
did not affect the poly I:C-induced
augmentation of AMPs and proin-
flammatory cytokines (Supplementary
Figure S4b).
When TLRs are activated via ligands,
the NF-kB signaling cascade is activated
and proinflammatory cytokines arewww.jidonline.org 727
